What's the outlook for ASX biotech shares in FY23?

ASX biotech shares could be changing course in FY23.

Key points
  • ASX biotech shares were a mixed bag in FY22
  • The outlook for the sector is mixed, but several names have caught a bid in early FY23
  • Here we look at three popular ASX biotech names

ASX biotech shares incurred heavy losses in FY22 as investors piled out of risk assets and moved into higher-quality corners of the market.

Here's a closer look at three noteworthy ASX biotech shares and their outlook for FY23.

Scientists in a laboratory look at a computer screen with anticipation on their faces.

Image source: Getty Images

CSL Ltd (ASX: CSL)

Shares in the biotech giant gyrated last year but analysts tip they'll deliver upside in FY23. Citi rates this ASX share a buy on a $330 valuation.

The Citi team say that CSL should benefit now that COVID-19 has wound back and blood plasma collections can resume en masse.

It forecasts around 20% growth in earnings per share (EPS) for CSL this financial year, as the market "shift[s] its focus to the strong underlying plasma product demand."

Not only that, but CSL announced its acquisition of Vifor Pharma last year, and is likely to book its first round of revenue from the transaction in FY23.

This could weigh on the CSL share price if everything goes well.

Imugene Ltd (ASX: IMU)

Shares in Imugene have caught a bid lately and are up 33% in the past week. After booking heavy losses last financial year, things could be looking different in FY23 for the ASX biotech share.

As TMF reported last week, "Imugene advised it has appointed a new executive director and clinical scientist."

That was Dr Sharon Yavrom, who comes with nearly 20 years of industry experience.

The latest results of its HER-Vaxx Phase 2 study were also a positive catalyst for the share price.

The HER-Vaxx segment is sure to be integral to Imugene's growth narrative looking ahead, as it was in FY22.

Immutep Ltd (ASX: IMM)

Another ASX biotech share worth mentioning for FY23 is Immutep. The company is focused on developing novel oncology solutions through its lead drug compound, etfi.

Immutep shares underperformed in FY22, with investors incurring a substantial on-paper loss. But the biotech share caught a bid in the first week of July following a company announcement.

Immutep advised that part A of the phase II TACTI-002 trial met its primary objective, showing favourable anti-tumour activity.

The study was evaluating efti in combination with MSD's pembrolizumab in 114 patients.

Investors reacted favourably after digesting the news.

The wider healthcare sector has also been strengthening in early FY23.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »